Reviewed by Jessica Munoz DPN, RN, CEN, providing nurse training at Yale New Haven Health-Bridgeport Hospital since 2022. Previously in healthcare and education at Griffin Hospital, St. Vincent's College of Nursing and Sacred Heart University Medical Center.
Cardio-oncology is an emerging specialty within cardiology focused on identifying, monitoring, and managing cardiovascular diseases that arise as side effects of radiotherapy or chemotherapy. Cardio-oncologists, who are essentially cardiologists, oversee the heart health of cancer survivors and patients currently undergoing cancer treatment. They are well-versed in the cardiac side effects associated with chemotherapy, targeted therapies, and radiation. Since this is a relatively new area in cardiology, many cities across the United States still lack dedicated cardio-oncologists.
Both chemotherapy and radiotherapy can lead to cardiac dysfunction, which significantly contributes to mortality and morbidity among cancer patients. Therefore, it is crucial to regularly monitor the cardiovascular health of patients undergoing cancer treatment.
Life-saving treatments such as chemotherapy and radiotherapy, while effective against cancer, can cause cardiovascular issues known as cardiotoxicity. This condition can manifest during cancer treatment, or it may appear days, months, or even years after the treatment has ended. Chemotherapy-induced cardiotoxicity can significantly reduce the quality of life and increase the risk of death due to cardiac complications.
Cancer treatments can impair the heart’s pumping efficiency, alter blood flow, and increase the risk of blood clots (thrombosis), potentially leading to a heart attack. Common heart conditions resulting from these changes include:
Other possible heart disorders due to cancer treatment include:
Not all cancer treatments cause cardiotoxicity, but many have the potential to damage the heart, including:
Individuals at higher risk for cardiotoxicity include those with preexisting heart disease or risk factors for heart disease, such as:
Certain chemotherapy drugs can damage heart muscles and blood vessels, increasing the risk of cardiotoxicity, especially in patients with underlying heart risk factors. Those undergoing radiation therapy in the chest area are also at higher risk due to the proximity of the heart to the radiation site.
Patients scheduled to receive potentially cardiotoxic therapy should undergo a comprehensive physical and cardiac evaluation before beginning cancer treatment. This evaluation helps doctors identify those at risk for cardiotoxicity and take necessary measures to reduce the patient’s risk. The evaluation may include:
Global strain is a new measure of heart muscle function determined through echocardiography with specialized computer technology. It allows for a more precise assessment of changes in heart function due to potentially cardiotoxic treatments.
The duration of these changes is still uncertain; some may be reversible, while others could be permanent.
Patients experiencing symptoms that may involve their heart should consult their oncologist or primary care doctor. Doctors can refer patients to a cardiologist or a cardio-oncologist if necessary. It’s important for patients to learn about potential side effects of cancer treatment so they can inform their healthcare team.
Patients showing symptoms of cardiotoxicity should visit a cardio-oncology center. These specialized centers involve a multidisciplinary group of specialists, including cardiologists, oncologists, cardiac surgeons, and nursing staff, who provide a comprehensive approach to diagnosing, evaluating, and treating cardiotoxicity.
Reviewed by Jessica Munoz DPN, RN, CEN, providing nurse training at Yale New Haven Health-Bridgeport Hospital since 2022. Previously in healthcare and education at Griffin Hospital, St. Vincent's College of Nursing and Sacred Heart University Medical Center.
More by this author: